Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Blood (2025) 146 (Supplement 1): 98.

https://doi.org/10.1182/blood-2025-98

Published: 2025

Journal Articles

N-glycosylation of monoclonal immunoglobulins across plasma cell dyscrasias in routine care: A cohort study using EXENT® mass spectrometry

Lauren Campbell, Oluremi Carty, Jessie Kaur, Jemma Larham, Ross Sadler, Anjan Thakurta, Udo Oppermann, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 7562.

https://doi.org/10.1182/blood-2025-7562

Published: 2025

Journal Articles

Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom

Blood (2025) 146 (Supplement 1): 4045.

https://doi.org/10.1182/blood-2025-4045

Published: 2025

Journal Articles

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Blood (2025) 146 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2025-2141

Published: 2025

Journal Articles

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Ravi Vij, Mark Fiala, David Cella, Brian Durie, David Kuter, Claudio Cerchione, Kamaraj Karunanithi, Jing Bo Li, Amanda Crosbie, Gabriela Hernandez-Rivera, Antoine Tinel, Thomas S. Marshall, Meghan Podolsky, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2025-6345

Published: 2025

Journal Articles

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Jemma Larham, Elizabeth Knight, Lauren Campbell, Jessie Kaur, Oluremi Carty, Constantinos Koshiaris, I-Jun Lau, Joe Browning, Jaimal Kothari, Sarah Gooding, Anjan Thakurta, Udo Oppermann, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2025-2185

Published: 2025

Journal Articles

AI-based analysis reveals novel blood protein biomarkers for predicting cardiac amyloidosis approximately a decade early: A UK biobank study

Seyed Alireza Hasheminasab, Berrin Balik, Joshua Fieggen, Lei Clifton, Nikant Sabharwal, Karthik Ramasamy, Ashutosh Wechalekar, Anjan Thakurta

Blood (2025) 146 (Supplement 1): 580.

https://doi.org/10.1182/blood-2025-580

Published: 2025

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Secure: A Prospective Long-Term Observational Study in Patients with Monoclonal Gammopathy of Undetermined Significance

Blood (2024) 144 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2024-203107

Published: 2024

Journal Articles

Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution

Blood (2024) 144 (Supplement 1): 669.

https://doi.org/10.1182/blood-2024-203306

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Naser Ansari-Pour, Mohammad Kazeroun, Seyed Alireza Hasheminasab, Emma J Lyon, Bethan Hudson-Lund, Evie Fitzsimons, Gaurav Agarwal, Kara-Louise Royle, Matthew W. Jenner, Martin F Kaiser, Karthik Ramasamy, Kwee Yong, Eileen M Boyle, Sarah Gooding, Angela Hamblin, Anjan Thakurta

Blood (2024) 144 (Supplement 1): 1909.

https://doi.org/10.1182/blood-2024-207973

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar

Blood (2024) 144 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2024-199773

Published: 2024

Journal Articles

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Ceri Bygrave, William Wilson, Rakesh Popat, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Michael A. Chapman, Ruth M de Tute, Selina J Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Fuad Fananapazir, Charlotte Tyson, Sumaiya Kamora, James D. Cavenagh, Roger G Owen, Kwee Yong

Blood (2024) 144 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2024-199514

Published: 2024

Journal Articles

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Blood (2024) 144 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2024-209772

Published: 2024

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

Symptom Burden in Idiopathic Multicentric Castleman Disease: Protocol for the Development of a Novel Standardized Patient Reported Outcome Measure

Sudipto Mukherjee, Philip A Powell, Jill Carlton, Clara Murukia, Antonio Adolfo Guerra Soares Brandão, Karthik Ramasamy, Frankie Shupo, Grace Wayi-Wayi, Karan Kanhai, Kelley C Dacus, Kelly Makarounas-Kirchmann, Anju Devianee Keetharuth

Blood (2023) 142 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2023-186256

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

N-glycosylation of monoclonal immunoglobulins across plasma cell dyscrasias in routine care: A cohort study using EXENT® mass spectrometry

Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

AI-based analysis reveals novel blood protein biomarkers for predicting cardiac amyloidosis approximately a decade early: A UK biobank study

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Secure: A Prospective Long-Term Observational Study in Patients with Monoclonal Gammopathy of Undetermined Significance

Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Symptom Burden in Idiopathic Multicentric Castleman Disease: Protocol for the Development of a Novel Standardized Patient Reported Outcome Measure

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only